HealthFDA Mandates New Warning for GLP-1 Drugs Amid Potential Blindness Risk
The FDA has ordered manufacturers of popular GLP-1 weight loss drugs like Ozempic and Wegovy to add a warning about a potential link to blindness caused by a rare eye condition called NAION. The agency cited research linking the drugs to the condition, though some manufacturers dispute the causal relationship.
The National|November 10, 2026 